Yanqiu Xing

Title: Yanqiu Xing: Innovator in Cancer Treatment

Introduction

Yanqiu Xing is a notable inventor based in Jinan, China. He has made significant contributions to the field of medicine, particularly in the treatment of non-small cell lung carcinoma. His innovative approach has led to the development of a unique strain that shows promise in cancer therapy.

Latest Patents

Yanqiu Xing holds a patent for the "Application of Derivatives of Clostridium Ghonii." This patent focuses on the application of derivatives, specifically the MW-DCG-HNCv-18 strain, in the preparation of medicines for treating non-small cell lung carcinoma. The invention reveals that the MW-DCG-HNCv-18 strain exhibits a specific inhibition effect on non-small cell lung carcinoma for the first time. The inhibition effect is significantly superior to that of other known similar strains. Furthermore, it has been discovered that the MW-DCG-HNCv-18 strain has a more prominent inhibition effect when combined with Docetaxel injection.

Career Highlights

Throughout his career, Yanqiu Xing has worked with various companies, including Shandong Xinchuang Biotechnology Co., Ltd. and Shihuida Pharmaceutical Group (Jilin) Co., Ltd. His work in these organizations has contributed to advancements in biotechnology and pharmaceuticals.

Collaborations

Yanqiu Xing has collaborated with notable colleagues, including Laitian Xing and Yong Wang. These partnerships have fostered innovation and research in the field of cancer treatment.

Conclusion

Yanqiu Xing's contributions to the medical field, particularly in cancer treatment, highlight his role as an innovator. His patented work demonstrates the potential of new strains in combating serious diseases. His ongoing research and collaborations continue to pave the way for advancements in medicine.